biostudies-literatureLumley SFSão Paulo Research FoundationNIHRInnovative Medicines InitiativeKennedy Trust for Rheumatology ResearchUK Government’s Department of Health and Social CareMedical Research CouncilNational Institute for Health Research (NIHR)Canada Foundation for InnovationKennedy TrustWellcome TrustGenome CanadaOntario Genomics InstitutePublic Health Englande699-e709https://www.ebi.ac.uk/biostudies/studies/S-EPMC7929225biostudies-literatureUnknown73(3)<h4>Background</h4>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) antibody measurements can be used to estimate the proportion of a population exposed or infected and may be informative about the risk of future infection. Previous estimates of the duration of antibody responses vary.<h4>Methods</h4>We present 6 months of data from a longitudinal seroprevalence study of 3276 UK healthcare workers (HCWs). Serial measurements of SARS-CoV-2 anti-nucleocapsid and anti-spike IgG were obtained. Interval censored survival analysis was used to investigate the duration of detectable responses. Additionally, Bayesian mixed linear models were used to investigate anti-nucleocapsid waning.<h4>Results</h4>Anti-spike IgG levels remained stably detected after a positiveClinical infectious diseases : an official publication of the Infectious Diseases Society of AmericaThe Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers.PMC7929225200915HDR-9006115766095541/A/11/ZMR/N00065X/1NF-SI-0508-10279G1100525NIHR200239NIHR300249214560/Z/18/Z110 110/Z/15/ZMC_UU_00008/6RP-PG-0514-20015OGI-055KENN202101106169/Z/14/ZYoung BHatton ENeville MJMartins DSzczurkowska JSutton CWright SBarot SSheehan RRobles MKirton RPattenden SPickford HKourdov SFerreira LMJames TTurford RTaylor AClay HMcgivern EPatel KChau KKScreaton GJurdon RDenly LEdwardes CAbbott MVilca KLynch RMccance APerera VDrennan PWharton VYoung ROxford University Hospitals Staff Testing GroupKumarendran MPikoula MMortimore EMarsh JRandhawa GMckinlay ASande NGunnell JAmini AD'Amato GEast CFadzillah NHMWedlich MOkuwoga TWozniak BMoroney RKelly GPonting JToward RShibu AWei JGergely BSims EPickles FWaite SCansdale LHatch SBWong WPeto TEAReed LRughani SMarsden BDChoudhury ZSimons EJEastwood BMentzer ABrent AConway-Jones RO'Byrne KThompson Cde Toledo ZSwann JYang-Turner FDunn PDowns LTill LDunlop EMcknight MKerneis SChakravorty TEvans MLivingstone AO'Donnell AMSharma ISkelly DHennessy CPeck LJJones NCann KJones SPetit YAxten DJesuthasan GFields CSomanathan ARylance-Knight LJohnson SJohnson TScott SFlaherty SKillen AManji AAston LSweeney OGates LGates MAlhussni AO'Donnell DSwift EHarris EThompson ZTamblyn MSalvagno CStuart DIMorrow JWilson JBodo NRay RNaude RTWLuciw MVorley IWilkins LAhmed-Firani TCornall RJFoord TFreer RDequaire JKhulusi BCutteridge JVogt ADavies TKerr SAndersson MJeffery KWalker ASVolk DPeto LSavva CDavies HBialek AJones EYPill GRitter TGCox VRodger GBack FGeorgiou DMyat SMason CLee CShaw RThomas SHarries CConlon CPDimitrov SGrassam-Rowe ALawson ECurtis ALumley SFHolland LJustice APhilips JKavanagh JHolland CMatthews PCGreenan-Barrett LTadikamalla GMitchell TDudareva MHolloway BVirgo CHoosdally SWareing SHowgego GCox SDanbury HBlack SMadsen TRigler CPouwels KBWatson LWalker TMJohnstone DSantos-Paulo SWatson ARavi KWhitty ADeales ALooms SHowarth AAnson KButcher LMullins HScharmeli AAbuelgasim HTamblin-Hopper PEyre DWTabirao MCrook DWBrennan IMighiu ASmit KWard HNevard HWard JMillar LBellinger TChristott TRothwell EDoherty GBarnham IJCronin TArgles INezhentsev AMohamed YShabir ZSussmes SAshworth RMillard RKarpe FEbner DWoodley HCampbell MSmith LStoesser NELawrence RAbhari RFowler PWMotohashi KFuchs HCameron SWarren FRobinson CLaurenson-Schafer HOliver MWarren LMorgan LfalseThe Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers.<h4>Background</h4>Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) antibody measurements can be used to estimate the proportion of a population exposed or infected and may be informative about the risk of future infection. Previous estimates of the duration of antibody responses vary.<h4>Methods</h4>We present 6 months of data from a longitudinal seroprevalence study of 3276 UK healthcare workers (HCWs). Serial measurements of SARS-CoV-2 anti-nucleocapsid and anti-spike IgG were obtained. Interval censored survival analysis was used to investigate the duration of detectable responses. Additionally, Bayesian mixed linear models were used to investigate anti-nucleocapsid waning.<h4>Results</h4>Anti-spike IgG levels remained stably detected after a positive2021-01-01T00:00:00Z2021 Aug2025-05-29T22:23:32.399Z2025-04-03T22:06:11.908ZS-EPMC79292253340078210.1093/cid/ciab004